Gsk Plc has bought stock on 14 days since Nov 2017
10% owner at Wave Life Sciences, Inc., and 11 other companies
SEC CIK 0001131399 · Filings on SEC.gov ↗
Gsk Plc's record
3 months after each buy, from the first price a copier could get.
3 buys since 2017 with 3 months of prices.
Companies
- WVE Wave Life Sciences, Inc.10% owner
- CVRX CVRx, Inc.10% owner
- INVA Innoviva, Inc.10% owner
- DBTX Decibel Therapeutics, Inc.Director
- BCYC Bicycle Therapeutics plc10% owner
- TPTX Turning Point Therapeutics, Inc.Director
- PGNY Progyny, Inc.10% owner
- PRNB Principia Biopharma Inc.Former 10% Owner
- MORF Morphic Holding, Inc.Director
- CCXI Churchill Capital Corp XIFormer 10% holder
- SPRO Spero Therapeutics, Inc.10% owner
- HTGM Htg Molecular Diagnostics, IncFormer 10% Owner
Every filing
19 filings since Mar 2017, newest first
Wave Life Sciences Ltd.
10% owner
Wave Life Sciences Ltd.
10% owner
Wave Life Sciences Ltd.
10% owner
Cvrx, Inc.
10% owner
Innoviva, Inc.
10% owner
Decibel Therapeutics, Inc.
Director
Bicycle Therapeutics Plc
10% owner
Turning Point Therapeutics, Inc.
Director
Progyny, Inc.
10% owner
Principia Biopharma Inc.
Former 10% Owner
Turning Point Therapeutics, Inc.
Director
Morphic Holding, Inc.
Director
Bicycle Therapeutics Plc
Director and 10% owner
Turning Point Therapeutics, Inc.
Director and 10% owner
Chemocentryx, Inc.
Former 10% holder
Principia Biopharma Inc.
10% owner
Spero Therapeutics, Inc.
10% owner
Spero Therapeutics, Inc.
10% owner
Htg Molecular Diagnostics, Inc
Former 10% Owner
About Gsk Plc
GSK plc (GlaxoSmithKline plc), commonly known as GSK, is a British multinational pharmaceutical and biotechnology company headquartered in London, England. Formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is one of the world's largest pharmaceutical companies, focusing on research, development, and manufacturing of medicines, vaccines, and consumer healthcare products.( The company operates globally with a strong emphasis on areas such as respiratory diseases, HIV, oncology, and infectious diseases, employing over 70,000 people worldwide.
As a major shareholder and 10% owner in Wave Life Sciences Ltd. (WVE), GSK plc recently engaged in significant insider trading activity, purchasing 2,791,930 shares on September 27, 2024, at $8.00 per share for approximately $22.34 million, and an additional 1,470,000 shares on December 11, 2025, for an estimated $27.93 million, increasing its holdings to 18,245,691 shares.( GSK is listed among WVE's key insiders alongside executives like CEO Paul Bolno.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.